glaxosmithkline plc europe will review diet drugs application glaxosmithkline plc said its marketing application for nonprescription orlistat a weight loss drug marketed as alli in the u s has been accepted for review by the european medicines agency the drug which went on sale in the u s in june is the only weight loss product approved by the food and drug administration that can be sold without a prescription alli is a less potent version of prescription weight loss drug xenical which was introduced in by swiss pharmaceutical company roche holding ag if its application is successful glaxosmithkline would be granted a license to market nonprescription orlistat in all european union member countries but the company hasnt said where it plans to introduce the product first 
